Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals.
Excellent balance sheet with proven track record.
Share Price & News
How has Beijing Tong Ren Tang Chinese Medicine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3613's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3613 underperformed the Hong Kong Pharmaceuticals industry which returned -2.5% over the past year.
Return vs Market: 3613 underperformed the Hong Kong Market which returned -9.9% over the past year.
Price Volatility Vs. Market
How volatile is Beijing Tong Ren Tang Chinese Medicine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDon't Sell Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Before You Read This
4 weeks ago | Simply Wall StRead This Before Selling Beijing Tong Ren Tang Chinese Medicine Company Limited (HKG:3613) Shares
Is Beijing Tong Ren Tang Chinese Medicine undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3613 (HK$9.3) is trading below our estimate of fair value (HK$9.74)
Significantly Below Fair Value: 3613 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 3613 is poor value based on its PE Ratio (14x) compared to the Pharmaceuticals industry average (10x).
PE vs Market: 3613 is poor value based on its PE Ratio (14x) compared to the Hong Kong market (9.3x).
Price to Earnings Growth Ratio
PEG Ratio: 3613 is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: 3613 is overvalued based on its PB Ratio (2.9x) compared to the HK Pharmaceuticals industry average (1.1x).
How is Beijing Tong Ren Tang Chinese Medicine forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3613's forecast earnings growth (10.1% per year) is above the savings rate (1.6%).
Earnings vs Market: 3613's earnings (10.1% per year) are forecast to grow slower than the Hong Kong market (16.5% per year).
High Growth Earnings: 3613's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3613's revenue (6.8% per year) is forecast to grow slower than the Hong Kong market (10.5% per year).
High Growth Revenue: 3613's revenue (6.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3613's Return on Equity is forecast to be high in 3 years time (20.1%)
How has Beijing Tong Ren Tang Chinese Medicine performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3613 has high quality earnings.
Growing Profit Margin: 3613's current net profit margins (38.8%) are higher than last year (38.4%).
Past Earnings Growth Analysis
Earnings Trend: 3613's earnings have grown by 14.5% per year over the past 5 years.
Accelerating Growth: 3613's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3613 had negative earnings growth (-4.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (2.7%).
Return on Equity
High ROE: 3613's Return on Equity (20.9%) is considered high.
How is Beijing Tong Ren Tang Chinese Medicine's financial position?
Financial Position Analysis
Short Term Liabilities: 3613's short term assets (HK$2.6B) exceed its short term liabilities (HK$307.1M).
Long Term Liabilities: 3613's short term assets (HK$2.6B) exceed its long term liabilities (HK$65.6M).
Debt to Equity History and Analysis
Debt Level: 3613's debt to equity ratio (0.04%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 3613's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: 3613's debt is well covered by operating cash flow (52327.6%).
Interest Coverage: 3613 earns more interest than it pays, so coverage of interest payments is not a concern.
What is Beijing Tong Ren Tang Chinese Medicine's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 3613's dividend (2.47%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.59%).
High Dividend: 3613's dividend (2.47%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.35%).
Stability and Growth of Payments
Stable Dividend: 3613 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 3613's dividend payments have increased, but the company has only paid a dividend for 7 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (34.6%), 3613's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 3613's dividends in 3 years are forecast to be well covered by earnings (37.3% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Huan Ping Zhang (59yo)
Mr. Zhang Huan Ping has been the Chief Executive Officer of Beijing Tong Ren Tang Chinese Medicine Company Limited since April 18, 2019. Mr. Ping served as the Deputy General Manager of Beijing Tong Ren Ta ...
CEO Compensation Analysis
Compensation vs Market: Huan Ping's total compensation ($USD232.32K) is below average for companies of similar size in the Hong Kong market ($USD506.58K).
Compensation vs Earnings: Huan Ping's compensation has been consistent with company performance over the past year.
|Chairman||1.17yrs||no data||0.042% HK$3.3m|
|CEO & Executive Director||1.08yrs||HK$1.80m||no data|
|COO & Executive Director||9.17yrs||HK$1.79m||0.030% HK$2.3m|
|Independent Non-Executive Director||2.67yrs||HK$240.00k||no data|
|Independent Non-Executive Director||7.08yrs||HK$240.00k||no data|
|Independent Non-Executive Director||7.08yrs||HK$240.00k||no data|
|Non-Executive Director||0.17yr||no data||no data|
Experienced Board: 3613's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Beijing Tong Ren Tang Chinese Medicine Company Limited's company bio, employee growth, exchange listings and data sources
- Name: Beijing Tong Ren Tang Chinese Medicine Company Limited
- Ticker: 3613
- Exchange: SEHK
- Founded: 1669
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$7.785b
- Shares outstanding: 837.10m
- Website: https://www.tongrentangcm.com
Number of Employees
- Beijing Tong Ren Tang Chinese Medicine Company Limited
- Office Tower
- Room 1405-1409
- Wan Chai
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|3613||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||May 2013|
|TQR||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 2013|
|3613||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||May 2013|
|3613||SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||May 2013|
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. The company operates in three segments: Hong Kong, PRC, and Overseas. It also offers Chinese medical consultation and treatment services. The company operates 71 retail outlets in 20 countries and regions. It markets its products under the Tong Ren Tang brand. The company was founded in 1669 and is based in Wanchai, Hong Kong. Beijing Tong Ren Tang Chinese Medicine Company Limited is a subsidiary of Tong Ren Tang Technologies Co., Ltd.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/30 13:37|
|End of Day Share Price||2020/05/29 00:00|